[en] OBJECTIVES: This study sought to evaluate the feasibility and safety of autologous bone marrow-derived and cardiogenically oriented mesenchymal stem cell therapy and to probe for signs of efficacy in patients with chronic heart failure. BACKGROUND: In pre-clinical heart failure models, cardiopoietic stem cell therapy improves left ventricular function and blunts pathological remodeling. METHODS: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) trial, a prospective, multicenter, randomized trial, was conducted in patients with heart failure of ischemic origin who received standard of care or standard of care plus lineage-specified stem cells. In the cell therapy arm, bone marrow was harvested and isolated mesenchymal stem cells were exposed to a cardiogenic cocktail. Derived cardiopoietic stem cells, meeting release criteria under Good Manufacturing Practice, were delivered by endomyocardial injections guided by left ventricular electromechanical mapping. Data acquisition and analysis were performed in blinded fashion. The primary endpoint was feasibility/safety at 2-year follow-up. Secondary endpoints included cardiac structure/function and measures of global clinical performance 6 months post-therapy. RESULTS: Mesenchymal stem cell cocktail-based priming was achieved for each patient with the dose attained in 75% and delivery without complications in 100% of cases. There was no evidence of increased cardiac or systemic toxicity induced by cardiopoietic cell therapy. Left ventricular ejection fraction was improved by cell therapy (from 27.5 +/- 1.0% to 34.5 +/- 1.1%) versus standard of care alone (from 27.8 +/- 2.0% to 28.0 +/- 1.8%, p < 0.0001) and was associated with a reduction in left ventricular end-systolic volume (-24.8 +/- 3.0 ml vs. -8.8 +/- 3.9 ml, p < 0.001). Cell therapy also improved the 6-min walk distance (+62 +/- 18 m vs. -15 +/- 20 m, p < 0.01) and provided a superior composite clinical score encompassing cardiac parameters in tandem with New York Heart Association functional class, quality of life, physical performance, hospitalization, and event-free survival. CONCLUSIONS: The C-CURE trial implements the paradigm of lineage guidance in cell therapy. Cardiopoietic stem cell therapy was found feasible and safe with signs of benefit in chronic heart failure, meriting definitive clinical evaluation. (C-Cure Clinical Trial; NCT00810238).
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Bartunek, Jozef
Behfar, Atta
Dolatabadi, Dariouch
Vanderheyden, Marc
Ostojic, Miodrag
Dens, Jo
El Nakadi, Badih
Banovic, Marko
Beleslin, Branko
Vrolix, Mathias
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics-2012 update: A report from the American Heart Association Circulation 125 2012 e2 e220
J.C. Kovacic, and V. Fuster From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020 Clin Pharmacol Ther 90 2011 509 518
O. Bergmann, R.D. Bhardwaj, and S. Bernard Evidence for cardiomyocyte renewal in humans Science 324 2009 98 102
J. Kajstura, K. Urbanek, and S. Perl Cardiomyogenesis in the adult human heart Circ Res 107 2010 305 315
N. Smart, S. Bollini, and K.N. Dubé De novo cardiomyocytes from within the activated adult heart after injury Nature 474 2011 640 644
J.J. McMurray Systolic heart failure N Engl J Med 362 2010 228 238
S. Dimmeler, A.M. Zeiher, and M.D. Schneider Unchain my heart: the scientific foundations of cardiac repair J Clin Invest 115 2005 572 583 (Pubitemid 40322227)
V.F. Segers, and R.T. Lee Stem-cell therapy for cardiac disease Nature 451 2008 937 942 (Pubitemid 351301749)
S. Janssens Stem cells in the treatment of heart disease Annu Rev Med 61 2010 287 300
K.C. Wollert, and H. Drexler Cell therapy for the treatment of coronary heart disease: A critical appraisal Nat Rev Cardiol 7 2010 204 215
A.M. Mozid, S. Arnous, E.C. Sammut, and A. Mathur Stem cell therapy for heart diseases Br Med Bull 98 2011 143 159
B. Assmus, J. Honold, and V. Schächinger Transcoronary transplantation of progenitor cells after myocardial infarction N Engl J Med 355 2006 1222 1232 (Pubitemid 44427446)
B.J. Gersh, R.D. Simari, A. Behfar, C.M. Terzic, and A. Terzic Cardiac cell repair therapy: A clinical perspective Mayo Clin Proc 84 2009 876 892
C.L. Mummery, R.P. Davis, and J.E. Krieger Challenges in using stem cells for cardiac repair Sci Transl Med 2 2010 27ps17
E. Chavakis, M. Koyanagi, and S. Dimmeler Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back Circulation 121 2010 325 335
J. Bartunek, M. Vanderheyden, J. Hill, and A. Terzic Cells as biologics for cardiac repair in ischaemic heart failure Heart 96 2010 792 800
P. Menasche Cardiac cell therapy: lessons from clinical trials J Mol Cell Cardiol 50 2011 258 265
L.M. Ptaszek, M. Mansour, J.N. Ruskin, and K.R. Chien Towards regenerative therapy for cardiac disease Lancet 379 2012 933 942
R. Bolli, A.R. Chugh, and D. D'Amario Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial Lancet 378 2011 1847 1857
R.R. Makkar, R.R. Smith, and K. Cheng Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial Lancet 379 2012 895 904
A. Behfar, and A. Terzic Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny Nat Clin Pract Cardiovasc Med 3 Suppl 1 2006 S78 S82
A. Behfar, S. Yamada, and R. Crespo-Diaz Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction J Am Coll Cardiol 56 2010 721 734
E. Marbán, and K. Malliaras Boot camp for mesenchymal stem cells J Am Coll Cardiol 56 2010 735 737
M. Mercola, P. Ruiz-Lozano, and M.D. Schneider Cardiac muscle regeneration: lessons from development Genes Dev 25 2011 299 309
M. Jessup, W.T. Abraham, and D.E. Casey ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 1343 1382
R. Crespo-Diaz, A. Behfar, and G.W. Butler Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability Cell Transplant 20 2011 797 811
A. Behfar, R.S. Faustino, D.K. Arrell, P.P. Dzeja, C. Perez-Terzic, and A. Terzic Guided stem cell cardiopoiesis: discovery and translation J Mol Cell Cardiol 45 2008 523 529
T.J. Nelson, A. Behfar, and A. Terzic Stem cells: biologics for regeneration Clin Pharmacol Ther 84 2008 620 623
J. Bartunek, W. Sherman, M. Vanderheyden, F. Fernandez-Aviles, W. Wijns, and A. Terzic Delivery of biologics in cardiovascular regenerative medicine Clin Pharmacol Ther 85 2009 548 552
P.J. Psaltis, A.C. Zannettino, S. Gronthos, and S.G. Worthley Intramyocardial navigation and mapping for stem cell delivery J Cardiovasc Transl Res 3 2010 135 146
J.S. Gottdiener, J. Bednarz, and R. Devereux American Society of Echocardiography recommendations for use of echocardiography in clinical trials J Am Soc Echocardiogr 17 2004 1086 1119
American Thoracic Society ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
M. Packer Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure J Card Fail 7 2001 176 182 (Pubitemid 32554111)
M. Banovic, M.C. Ostojic, J. Bartunek, M. Nedeljkovic, B. Beleslin, and A. Terzic Brachial approach to NOGA-guided procedures: electromechanical mapping and transendocardial stem-cell injections Tex Heart Inst J 38 2011 179 182
J.M. Hare, J.H. Traverse, and T.D. Henry A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction J Am Coll Cardiol 54 2009 2277 2286
T.S. Rector A conceptual model of quality of life in relation to heart failure J Cardiac Failure 11 2005 173 176 (Pubitemid 40462418)
J.H. Traverse, T.D. Henry, and S.G. Ellis Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial JAMA 306 2011 2110 2119
D.W. Losordo, T.D. Henry, and C. Davidson Intramyocardial, autologous CD34+ cell therapy for refractory angina Circ Res 109 2011 428 436
V. Schachinger, S. Erbs, and A. Elsasser Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction N Engl J Med 355 2006 1210 1221 (Pubitemid 44427445)
J.H. Traverse, T.D. Henry, and C.J. Pepine Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: The TIME randomized trial JAMA 308 2012 2380 2389
A.R. Williams, B. Trachtenberg, and D.L. Velazquez Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling Circ Res 108 2011 792 796
K. Malliaras, M. Kreke, and E. Marbán The stuttering progress of cell therapy for heart disease Clin Pharmacol Ther 90 2011 532 541
K.E. Hatzistergos, H. Quevedo, and B.N. Oskouei Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation Circ Res 107 2010 913 922
M.J. Lovell, and A. Mathur Cardiac stem cell therapy: progress from the bench to bedside Heart 96 2010 1531 1537
A.R. Williams, and J.M. Hare Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease Circ Res 109 2011 923 940
J.M. Hare, J.E. Fishman, and G. Gerstenblith Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial JAMA 308 2012 2369 2379
E. Marbán, and K. Malliaras Mixed results for bone marrow-derived cell therapy for ischemic heart disease JAMA 308 2012 2405 2406
J.A. Epstein Cardiac development and implications for heart disease N Engl J Med 363 2010 1638 1647
M.S. Penn, F. Dong, S. Klein, and M.E. Mayorga Stem cells for myocardial regeneration Clin Pharmacol Ther 90 2011 499 501
S. Mohsin, S. Siddiqi, B. Collins, and M.A. Sussman Empowering adult stem cells for myocardial regeneration Circ Res 109 2011 1415 1428
A. Stolzing, E. Jones, D. McGonagle, and A. Scutt Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies Mech Ageing Dev 129 2008 163 173
M. Lioznov, C. Dellbrügger, A. Sputtek, B. Fehse, N. Kröger, and A.R. Zander Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM Bone Marrow Transplant 42 2008 121 128
M. St John Sutton, M.A. Pfeffer, and L. Moye Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial Circulation 96 1997 3294 3299 (Pubitemid 27513397)
S.D. Solomon, N. Anavekar, and H. Skali Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients Circulation 112 2005 3738 3744 (Pubitemid 43739514)
A. Terzic, and T.J. Nelson Regenerative medicine advancing health care 2020 J Am Coll Cardiol 55 2010 2254 2257
S.F. Badylak, D.J. Weiss, A. Caplan, and P. Macchiarini Engineered whole organs and complex tissues Lancet 379 2012 943 952
S.A. Waldman, and A. Terzic Cardiovascular health: the global challenge Clin Pharmacol Ther 90 2011 483 485
A. Terzic, and S. Waldman Chronic diseases: the emerging pandemic Clin Transl Sci 4 2011 225 226
B.E. Strauer, and G. Steinhoff 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice J Am Coll Cardiol 58 2011 1095 1104
E.C. Perin, J.T. Willerson, and C.J. Pepine Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial JAMA 307 2012 1717 1726
K.R. Brunt, R.D. Weisel, and R.K. Li Stem cells and regenerative medicine-future perspectives Can J Physiol Pharmacol 90 2012 327 335
